EUCTR2004-001252-36-IT进行中（未招募）不适用
DOUBLE BLIND, RANDOMISED, PARALLEL GROUP, MULTICENTRE STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF CHF 1521 (FIXED COMBINATION OF MANIDIPINE AND DELAPRIL) VS LOSARTAN 50 MG AND HYDROCHLOROTHIAZIDE 12.5 MG IN TYPE 2 DIABETIC HYPERTENSIVE PATIENTS.The MORE study (Manidipine and delapril vs losartan and HCTZ in diabetic patients, 24 hour blood pressure).
CHIESI0 个研究点开始时间: 2004年9月16日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
DOUBLE BLIND, RANDOMISED, PARALLEL GROUP, MULTICENTRE STUDY TO EVALUATE THE EFFECTS OF MANIDIPINE 20 MG VS AMLODIPINE 10 MG AND THE COMBINATION OF MANIDIPINE 10 MG PLUS DELAPRIL 30 MG VS AMLODIPINE 5 MG PLUS DELAPRIL 30 MG ON INTRAGLOMERULAR PRESSURE IN HYPERTENSIVE PATIENTS. - MANTRAmild to moderate essential hypertension.EUCTR2006-006350-10-DEChiesi Farmaceutici100
进行中（未招募）
不适用
Double-Blind, Randomized, Parallel Group, Multicenter Study of Durolane Compared to Methylprednisolone in Subjects with Osteoarthritis of the KneeEUCTR2006-006485-42-SEQ-Med AB432
进行中（未招募）
1 期
Double-Blind, Randomized, Parallel Group, Multicenter Study of Durolane Compared to Methylprednisolone in Subjects with Osteoarthritis of the KneeEUCTR2006-006485-42-GBQ-Med AB432
进行中（未招募）
不适用
A PARALLEL-GROUP, RANDOMIZED, DOUBLE-BLIND, MULTI-CENTER DOSE RESPONSE STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF- 00885706, A 5-HT4 RECEPTOR PARTIAL AGONIST, AS ADD-ON THERAPY TO ESOMEPRAZOLE FOR THE RELIEF OF SYMPTOMS IN SUBJECTS WITH GASTRO-ESOPHAGEAL REFLUX DISEASE (GERD) WHO HAVE A POOR RESPONSE TO PROTON PUMP INHIBITOR (PPI) TREATMENTGASTRO-ESOPHAGEAL REFLUX DISEASE (GERD)MedDRA version: 9.1Level: LLTClassification code 10018203Term: GERDEUCTR2007-001487-67-BEPfizer Limited, Ramsgate Road, Sandwich, CT13 9NJ Kent, UK450
进行中（未招募）
不适用
A PARALLEL-GROUP, RANDOMIZED, DOUBLE-BLIND, MULTI-CENTER DOSE RESPONSE STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF- 00885706, A 5-HT4 RECEPTOR PARTIAL AGONIST, AS ADD-ON THERAPY TO ESOMEPRAZOLE FOR THE RELIEF OF SYMPTOMS IN SUBJECTS WITH GASTRO-ESOPHAGEAL REFLUX DISEASE (GERD) WHO HAVE A POOR RESPONSE TO PROTON PUMP INHIBITOR (PPI) TREATMENTGASTRO-ESOPHAGEAL REFLUX DISEASE (GERD)MedDRA version: 9.1Level: LLTClassification code 10018203Term: GERDEUCTR2007-001487-67-DEPfizer Limited, Ramsgate Road, Sandwich, Kent, UK450